Abstract 220P
Background
Radiation oral mucositis (radiotherapy-induced oral mucositis, RIOM), as one of the common complications during radiotherapy, is difficult to avoid and predict. Severe RIOM will reduce the quality of life of patients and affect the normal progress of diagnosis and treatment. Early detection and early intervention is very important to reduce the incidence of RIOM, but at present, the sensitivity and specificity of clinical indicators for the occurrence and development of radiation stomatitis are poor, so it is necessary to study further the treatment factors and predictive indicators of radiation stomatitis. It has been found that oral flora are closely related to the progression of radiation oral mucositis.
Methods
27 postoperative patients with oral squamous cell carcinoma were enrolled in the study. The cotton swab samples of oral buccal mucosa before and after radiotherapy were collected. The diversity, species differences and marker species of the oral microbial community were determined by 16 S rRNA sequencing and metagenome sequencing.
Results
Compared with the pre-radiotherapy group, the composition of oral flora in the radiotherapy group and the post-radiotherapy group changed, and the community diversity decreased significantly. The richness of different flora was different. In terms of genera, there was a difference in the richness of Haemophilus during radiotherapy, after radiotherapy and before radiotherapy, and the number of different bacteria was positively correlated with the time of radiotherapy. At the species level, the diversity of Streptococcus pneumoniae and Haemophilus haemolyticus increased significantly after radiotherapy. In terms of functional distribution, based on KEGG and CAZymes database, there were differences in functional distribution between the two groups of oral flora.
Conclusions
Radiotherapy can change the species structure and composition of oral flora and reduce community diversity. Streptococcus pneumoniae and Haemophilus haemolyticus may be related to the occurrence and development of radiation oral mucositis.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session